Literature DB >> 17333037

[Lymphadenectomy with tumors of the upper gastrointestinal tract].

C Schuhmacher1, A Novotny, K Ott, M Feith, J R Siewert.   

Abstract

In surgical therapy for upper gastrointestinal cancer, adequate lymphadenectomy together with R0 resection of the primary tumour is one of the most important prognostic factors which can be influenced by the surgeon. Recommendations for localization- and stage-adapted lymphadenectomy can be made according to histopathologic and anatomic investigations of the patient collectives of large centres. After neoadjuvant radiochemotherapy in cancer of the cervical oesophagus, the absence of lymph nodes on the resected specimen seems to be of less prognostic value. In squamous cell cancer of the suprabifurcal oesophagus, radical lymphadenectomy is recommended. Despite significant morbidity, in specialized centres this procedure yields good results with low mortality. For infrabifurcal oesophageal cancer, two-field lymphadenectomy during the so-called Ivor-Lewis operation is the method of choice. Locally advanced Barrett carcinoma is also an indication for classic two-field lymphadenectomy together with abdominothoracic oesophagectomy and creation of a stomach tube with intrathoracic anastomosis. The lymphadenectomy should however include the area of retroperitoneal lymphatic drainage at the pedicle of the left kidney. Submucosal cancer in this area can be treated with luminal limited resection of the oesophagogastric junction with adequate lymphadenectomy. Adenocarcinoma of the cardia and subcardial gastric cancer including the cardia both require lymphadenectomy analogous to that performed in gastric cancer, with special attention paid to the retroperitoneal lymphatic drainage towards the left kidney pedicle. For therapy of gastric cancer, a systematic D2 lymphadenectomy should always be performed.

Entities:  

Mesh:

Year:  2007        PMID: 17333037     DOI: 10.1007/s00104-007-1307-7

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  23 in total

1.  [Response prediction--early response evaluation. Consequences for surgical oncology].

Authors:  J R Siewert; F Lordick
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

2.  Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial. The Surgical Cooperative Group.

Authors:  A Cuschieri; P Fayers; J Fielding; J Craven; J Bancewicz; V Joypaul; P Cook
Journal:  Lancet       Date:  1996-04-13       Impact factor: 79.321

3.  Adenocarcinoma of the esophagogastric junction: surgical therapy based on 1602 consecutive resected patients.

Authors:  Marcus Feith; Hubert J Stein; J Rüdiger Siewert
Journal:  Surg Oncol Clin N Am       Date:  2006-10       Impact factor: 3.495

4.  Computer analysis in making preoperative decisions: a rational approach to lymph node dissection in gastric cancer patients.

Authors:  G H Kampschöer; K Maruyama; C J van de Velde; M Sasako; T Kinoshita; K Okabayashi
Journal:  Br J Surg       Date:  1989-09       Impact factor: 6.939

5.  Limited resection for early adenocarcinoma in Barrett's esophagus.

Authors:  H J Stein; M Feith; J Mueller; M Werner; J R Siewert
Journal:  Ann Surg       Date:  2000-12       Impact factor: 12.969

6.  Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial.

Authors:  K C M J Peeters; S A Hundahl; E Klein Kranenbarg; H Hartgrink; C J H van de Velde
Journal:  World J Surg       Date:  2005-12       Impact factor: 3.352

7.  Association of the primary tumor location with the site of tumor recurrence after curative resection of thoracic esophageal carcinoma.

Authors:  Yuichiro Doki; Osamu Ishikawa; Ko Takachi; Isao Miyashiro; Yo Sasaki; Hiroaki Ohigashi; Kohei Murata; Terumasa Yamada; Shingo Noura; Hidetoshi Eguchi; Toshiyuki Kabuto; Shingi Imaoka
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.352

8.  Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501.

Authors:  Takeshi Sano; Mitsuru Sasako; Seiichiro Yamamoto; Atsushi Nashimoto; Akira Kurita; Masahiro Hiratsuka; Toshimasa Tsujinaka; Taira Kinoshita; Kuniyoshi Arai; Yoshitaka Yamamura; Kunio Okajima
Journal:  J Clin Oncol       Date:  2004-06-15       Impact factor: 44.544

9.  Morbidity and mortality after D1 and D2 gastrectomy for cancer: interim analysis of the Italian Gastric Cancer Study Group (IGCSG) randomised surgical trial.

Authors:  M Degiuli; M Sasako; M Calgaro; M Garino; F Rebecchi; M Mineccia; D Scaglione; D Andreone; A Ponti; F Calvo
Journal:  Eur J Surg Oncol       Date:  2004-04       Impact factor: 4.424

10.  Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer.

Authors:  H Bartels; H J Stein; J R Siewert
Journal:  Br J Surg       Date:  1998-06       Impact factor: 6.939

View more
  3 in total

Review 1.  Gastric cancer: surgery in 2011.

Authors:  Katja Ott; Florian Lordick; Susanne Blank; Markus Büchler
Journal:  Langenbecks Arch Surg       Date:  2011-01-14       Impact factor: 3.445

2.  [Diagnosis and treatment of esophageal cancer].

Authors:  R Kiesslich; M Möhler; T Hansen; P R Galle; H Lang; I Gockel
Journal:  Internist (Berl)       Date:  2012-11       Impact factor: 0.743

3.  [Esophageal carcinoma].

Authors:  J R Siewert
Journal:  Chirurg       Date:  2007-05       Impact factor: 0.955

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.